Chemomab Therapeutics Announces ADS Ratio Adjustment
Ticker: CMMB · Form: 6-K · Filed: Aug 22, 2025 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 6-K |
| Filed Date | Aug 22, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, ADS-adjustment
TL;DR
Chemomab is adjusting its ADS to share ratio, details to follow.
AI Summary
Chemomab Therapeutics Ltd. announced on August 22, 2025, that it will implement a ratio adjustment for its American Depositary Shares (ADSs) relative to its ordinary shares. The specific details of this ratio adjustment were not disclosed in this filing.
Why It Matters
This filing indicates a change in the share structure for Chemomab's ADSs, which could impact trading dynamics and investor perception.
Risk Assessment
Risk Level: low — The filing is an announcement of a corporate action (ADS ratio adjustment) and does not contain material financial or operational news that would immediately impact risk.
Key Players & Entities
- Chemomab Therapeutics Ltd. (company) — Registrant
- Anchiano Therapeutics Ltd. (company) — Former company name
- BioCancell Ltd. (company) — Former company name
FAQ
What is the new ratio for the American Depositary Shares (ADSs) to ordinary shares?
The filing announces that a ratio adjustment will be effected, but the specific new ratio is not disclosed.
When will the ADS ratio adjustment take effect?
The filing does not specify an effective date for the ADS ratio adjustment.
What is the purpose of this ADS ratio adjustment?
The filing does not state the specific purpose behind the ADS ratio adjustment.
Has Chemomab Therapeutics Ltd. undergone name changes previously?
Yes, Chemomab Therapeutics Ltd. was formerly known as Anchiano Therapeutics Ltd. (since 20180906) and prior to that, BioCancell Ltd. (since 20111104).
What is the primary business of Chemomab Therapeutics Ltd. according to the filing?
The filing lists the Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 358 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2025-08-22 16:05:14
Filing Documents
- zk2533691.htm (6-K) — 10KB
- 0001178913-25-003015.txt ( ) — 11KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant's name into English) 6 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE Chemomab Therapeutics Ltd. (the "Company") is announcing that it will effect a ratio adjustment of its American Depositary Shares (ADSs) to ordinary shares, no par value ("ordinary shares"), such that the current ratio of one (1) ADS representing twenty (20) ordinary shares will change to a new ratio of one (1) ADS representing eighty (80) ordinary shares (the "Ratio Change"), which Ratio Change will take effect on August 26, 2025. This ratio adjustment will essentially serve as a one-for-four reverse ADS split for ADS holders, requiring no action on their part. The Company will continue to be traded on the Nasdaq Capital Market under the ticker "CMMB", with an updated CUSIP Number of 16385C203. The Bank of New York Mellon, serving as the depositary bank for the Company's ADS program, will arrange for the exchange of every four existing ADSs held for one new ADS on the effective date. There will be no issuance of new ADSs in connection with the adjustment. Any fractional shares resulting from the adjustment will be aggregated and the depositary bank will attempt to sell them and distribute the net proceeds to the respective ADS holders. This Report on Form 6-K is hereby incorporated by reference into Company's Registration Statements on Form F-3 (File No. 333-275002 and No. 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CHEMOMAB THERAPEUTICS LTD. Date: August 22, 2025 By: /s/ Sigal Fattal Sigal Fattal Chief Financial Officer